1+ day, 7+ hour ago  (189+ words) 19 June 2026 | Friday | News Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms 10x'Genomics, Inc. (Nasdaq:'TXG), the life science technology leader focused on accelerating science and advancing human health, announced…...

1+ day, 8+ hour ago  (549+ words) Bio Pharma APAC - Sonire Lands Major Japanese Government Backing to Advance Next-Generation Cancer Ultrasound Therapy 19 June 2026 | Friday | News Non-dilutive funding will support the commercialization, development, and expansion strategy for Sonire's Ultrasound-Guided HIFU Platform Sonire Therapeutics, a U. S. -based clinical-stage medical device…...

1+ day, 7+ hour ago  (559+ words) Bio Pharma APAC - Wu Xi Biologics Strengthens Regulatory Credentials with Repeat EMA GMP Approval 19 June 2026 | Friday | News Wu Xi Biologics (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety Testing Center in Suzhou has…...

1+ day, 5+ hour ago  (314+ words) 19 June 2026 | Friday | Analysis Taken together, these are not incremental upgrades. They are a regional wager " placed almost simultaneously by three of Asia's most ambitious manufacturers " that the antibody-drug conjugate will be the defining oncology modality of the next decade, and…...

3+ day, 8+ hour ago  (465+ words) Bio Pharma APAC - Pelago Bioscience Acquires RG Discovery to Create Integrated Chemistry-to-Biology Drug Discovery Platform 17 June 2026 | Wednesday | News Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to…...

3+ day, 7+ hour ago  (566+ words) Bio Pharma APAC - Akeso Enrols First Patient in Phase Ib/II Trial of Next-Generation HER3 ADC AK138 D1 for Advanced Breast Cancer 17 June 2026 | Wednesday | News Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical…...

3+ day, 16+ hour ago  (199+ words) 16 June 2026 | Tuesday | Analysis The question for Asia, then, is not whether to go faster. That decision has effectively been made. The question is whether the surveillance, the confirmatory-evidence discipline and the willingness to reverse a bad approval are being built…...

4+ day, 1+ hour ago  (654+ words) Bio Pharma APAC - Harbour Bio Med's Antibody Innovation Prevails in Major Patent Clash with Amgen 16 June 2026 | Tuesday | News - The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody…...

4+ day, 3+ hour ago  (177+ words) 16 June 2026 | Tuesday | News Validated targets cover Scope 1, 2 and 3 emissions, including a supplier engagement commitment reaching 67% of suppliers by spend by 2030 "These goals aren't just a commitment, they represent a verified plan with third-party accountability built in," says Corey Meek, Corporate…...

4+ day, 7+ hour ago  (259+ words) 16 June 2026 | Tuesday | News BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with'the majority of'patients previously treated with a covalent BTK inhibitor, reflects current practice patterns Eli Lilly and Company announced results…...